Literature for peptidase C01.032: cathepsin L

(References are filtered for relevance to Structure. To remove the filter click here. See explanation.)

2016
1. Sosnowski,P. and Turk,D.
   Caught in the act: the crystal structure of cleaved cathepsin L bound to the active site of cathepsin L
   FEBS Lett590, 1253-1261. PubMed  Europe PubMed DOI  S
2011
2. Adams-Cioaba,M.A., Krupa,J.C., Xu,C., Mort,J.S. and Min,J.
   Structural basis for the recognition and cleavage of histone H3 by cathepsin L
   Nat Commun2, 197-197. PubMed  Europe PubMed DOI  S
3. Hardegger,L.A., Kuhn,B., Spinnler,B., Anselm,L., Ecabert,R., Stihle,M., Gsell,B., Thoma,R., Diez,J., Benz,J., Plancher,J.M., Hartmann,G., Isshiki,Y., Morikami,K., Shimma,N., Haap,W., Banner,D.W. and Diederich,F.
   Halogen bonding at the active sites of human cathepsin L and MEK1 kinase: efficient interactions in different environments
   ChemMedChem6, 2048-2054. PubMed  Europe PubMed DOI  S
2009
4. Shenoy,R.T., Chowdhury,S.F., Kumar,S., Joseph,L., Purisima,E.O. and Sivaraman,J.
   A combined crystallographic and molecular dynamics study of cathepsin L retrobinding inhibitors
   J Med Chem52, 6335-6346. PubMed  Europe PubMed DOI  S  I
2008
5. Chowdhury,S.F., Joseph,L., Kumar,S., Tulsidas,S.R., Bhat,S., Ziomek,E., Menard,R., Sivaraman,J. and Purisima,E.O.
   Exploring inhibitor binding at the S' subsites of cathepsin L
   J Med Chem51, 1361-1368. PubMed  Europe PubMed DOI  S  I
6. Fairhead,M., Johnson,K.A., Kowatz,T., McMahon,S.A., Carter,L.G., Oke,M., Liu,H., Naismith,J.H. and van der Walle,C.F.
   Crystal structure and silica condensing activities of silicatein alpha-cathepsin L chimeras
   Chem Commun (Camb)2008, 1765-1767. PubMed  Europe PubMed DOI  S
7. Shah,P.P., Myers,M.C., Beavers,M.P., Purvis,J.E., Jing,H., Grieser,H.J., Sharlow,E.R., Napper,A.D., Huryn,D.M., Cooperman,B.S., Smith,A.B., III and Diamond,S.L.
   Kinetic characterization and molecular docking of a novel, potent, and selective slow-binding inhibitor of human cathepsin L
   Mol Pharmacol74, 34-41. PubMed  Europe PubMed DOI  S  I
2002
8. [YEAR:21-11-2002]Chowdhury,S.F., Sivaraman,J., Wang,J., Devanathan,G., Lachance,P., Qi,H., Menard,R., Lefebvre,J., Konishi,Y., Cygler,M., Sulea,T. and Purisima,E.O.
   Design of noncovalent inhibitors of human cathepsin L. From the 96-residue proregion to optimized tripeptides
   J Med Chem45, 5321-5329. PubMed  Europe PubMed DOI  S  I
1999
9. [YEAR:15-2-1999]Guncar,G., Pungercic,G., Klemencic,I., Turk,V. and Turk,D.
   Crystal structure of MHC class II-associated p41 Ii fragment bound to cathepsin L reveals the structural basis for differentiation between cathepsins L and S
   EMBO J18, 793-803. PubMed  Europe PubMed DOI  S
1997
10. Fujishima,A., Imai,Y., Nomura,T., Fujisawa,Y., Yamamoto,Y. and Sugawara,T.
    The crystal structure of human cathepsin L complexed with E-64
    FEBS Lett407, 47-50. PubMed  Europe PubMed DOI  S  I
1996
11. Coulombe,R., Grochulski,P., Sivaraman,J., Menard,R., Mort,J.S. and Cygler,M.
    Structure of human procathepsin L reveals the molecular basis of inhibition by the prosegment
    EMBO J15, 5492-5503. PubMed  Europe PubMed  E  S
12. Coulombe,R., Li,Y., Takebe,S., Menard,R., Mason,P., Mort,J.S. and Cygler,M.
    Crystallization and preliminary X-ray diffraction studies of human procathepsin L
    Proteins25, 398-400. PubMed  Europe PubMed DOI  S